An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus

Epidemiology and Infection

Volumn 137, Issue 9, 2009, Pages 1309-1318

  Heise, M T ^a,b   Whitmore, A ^b   Thompson, J ^a,b   Parsons, M ^a,b   Grobbelaar, A A ^c   Kemp, A ^c   Paweska, J T ^c   Madric, K ^a,b   White, L J ^a,b   Swanepoel, R ^c   Burt, F J ^c,d,e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^e UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

Alphavirus replicon; Rift Valley fever virus; Vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; RIFT VALLEY FEVER VIRUS VACCINE; SINGLE STRANDED RNA; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS MESSENGER RNA; VIRUS VACCINE;

ALPHA VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FLUORESCENCE; HEMORRHAGIC FEVER; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOASSAY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REPLICON; RIFT VALLEY FEVER BUNYAVIRUS; SHEEP; SINDBIS VIRUS; VIRUS NEUTRALIZATION;

ANIMALS; MICE; REPLICON; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SHEEP; SINDBIS VIRUS; VIRAL VACCINES;

EID: 69949178850     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268808001696     Document Type: Article

References (41)

1. Swanepoel R, Coetzer JAW. Rift Valley Fever. In: Coetzer JAW, Tustin RC, eds. Infectious Diseases of Livestock. Cape Town: Oxford University Press, 2004, pp. 1037-1070.
2. Fontenille D, et al. New vectors of Rift Valley fever in West Africa. Emerging Infectious Diseases 1998; 4: 289-293.
3. Gargan 2nd TP, et al. Vector potential of selected North American mosquito species for Rift Valley fever virus. American Journal of Tropical Medicine and Hygiene 1988; 38: 440-446.
4. Sidwell RW, Smee DF. Viruses of the Bunya- and Togaviridae families: Potential as bioterrorism agents and means of control. Antiviral Research 2003; 57: 101-111.
5. Smithburn KC. Rift Valley Fever: The neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. British Journal of Experimental Pathology 1949; 30: 1-16.
6. Barnard BJ. Rift Valley fever vaccine - antibody and immune response in cattle to a live and an inactivated vaccine. Journal of the South African Veterinary Association 1979; 50: 155-157.
7. Meadors GF, Gibbs PH, Peters CJ. Evaluation of a new Rift Valley fever vaccine: Safety and immunogenicity trials. Vaccine 1986; 4: 179-184.
8. Pittman PR, et al. Immunogenicity of aninactivated Rift Valley fever vaccine in humans: A 12 year experience. Vaccine 1999; 18: 181-189.
9. Hunter P, Erasmus BJ, Vorster JH. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort Journal of Veterinary Research 2002; 69: 95-98.
10. Morrill JC, et al. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine 1991; 9: 35-41.
11. Frolov I, et al. Alphavirus-based expression vectors: strategies and applications. Proceedings of the National Academy of Sciences USA 1996; 93: 11371-11377.
12. Hevey M, et al. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251: 28-37.
13. Pushko P, et al. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. Journal of Virology 2001; 75: 11677-11685.
14. Nichol ST. Bunyaviruses. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams and Wilkins, 2001, pp. 1603-1633.
15. Schmaljohn CS, Hooper JW. Bunyaviridae: The viruses and their replication. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams and Wilkins, 2001, pp. 1581-1602.
16. Swanepoel R. Observations on Rift Valley fever in Zimbabwe. Contributions to Epidemiology and Biostatistics 1981; 3: 83-91.
17. Francis T, Magill TP. Rift Valley Fever: A report of three cases of laboratory infection and the experimental transmission of the disease to ferrets. Journal of Experimental Medicine 1935; 62: 433-448.
18. Peters CJ, et al. Experimental Rift Valley fever in rhesus macaques. Archives of Virology 1988; 99: 31-44.
19. Schmaljohn CS, et al. Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 1989; 170: 184-192.
20. Malherbe H, Strickland-Cholmley M, Jackson AL. Sindbis virus infection in man. Report of a case with recovery of virus from skin lesions. South African Medical Journal 1963; 37: 547-552.
21. Weinbren MP, Kokernot RH, Smithburn KC. Strains of Sindbis-like virus isolated from culicine mosquitoes in the Union of South Africa. South African Medical Journal 1956; 30: 631-636.
22. Heise MT, Simpson DA, Johnston RE. Sindbis-group alphavirus replication in periosteum and endosteum of long bones in adult mice. Journal of Virology 2000; 74: 9294-9299.
23. Suthar MS, et al. Identification of adult mouse neurovirulence determinants of the Sindbis virus strain AR86. Journal of Virology 2005; 79: 4219-4228.
24. Collett MS, et al. Complete nucleotide sequence of the M RNA segment of Rift Valley fever virus. Virology 1985; 144: 228-245.
25. Filone CM, et al. Development and characterization of a Rift Valley fever virus cell-cell fusion assay using alphavirus replicon vectors. Virology 2006; 356: 155-164.
26. Winter G, Fields S, Brownlee GG. Nucleotide sequence of the haemagglutinin gene of a human influenza virus H1 subtype. Nature 1981; 292: 72-75.
27. Deming D, et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Medicine 2006; 3: E525.
28. Balasuriya UB, et al. Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine 2002; 20: 1609-1617.
29. Swanepoel R, et al. Comparison of techniques for demonstrating antibodies to Rift Valley fever virus. Journal of Hygiene (London) 1986; 97: 317-329.
30. Heise MT, Simpson DA, Johnston RE. A single amino acid change in nsP1 attenuates neurovirulence of the Sindbis-group alphavirus, S.A.AR86. Journal of Virology 2000; 74: 4207-4213.
31. Simpson DA, et al. Complete nucleotide sequence and full-length cDNA clone of S.A.AR86 a South African alphavirus related to Sindbis. Virology 1996; 222: 464-469.
32. McIntosh BM, et al. Antibodies against certain arboviruses in the sera of human beings and domestic animals from the South African highveld. South African Journal of Medical Sciences 1962; 27 87-94.
33. Taylor RM, et al. Sindbis virus: A newly recognized arthropod-transmitted virus. American Journal of Tropical Medicine and Hygiene 1955; 4: 844-862.
34. Gorchakov R, et al. Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins. Virology 2007; 366: 212-225.
35. Brown JL, Dominik JW, Morrissey RL. Respiratory infectivity of a recently isolated Egyptian strain of Rift Valley fever virus. Infection and Immunity 1981; 33: 848-853.
36. Hoogstraal H, et al. The Rift Valley fever epizootic in Egypt 1977-78. 2. Ecological and entomological studies. Transactions of the Royal Society of Tropical Medicine and Hygiene 1979; 73: 624-629.
37. Keefer GV, Zebarth GL, Allen WP. Susceptibility of dogs and cats to Rift Valley fever by inhalation or ingestion of virus. Journal of Infectious Diseases 1972; 125: 307-309.
38. Miller WS, et al. Stability and infectivity of airborne yellow fever and Rift Valley fever viruses. American Journal of Hygiene 1963; 77: 114-121.
39. Anderson GW, et al. Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats. Vaccine 1991; 9 710-714.
40. LoBue AD, et al. Multivalent norovirus vaccines induce Strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 2006; 24: 5220-5234.
41. Thompson JM, et al. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proceedings of the National Academy of Sciences USA 2006; 103: 3722-3727.